AI is spitting out more potential drugs than ever. This start-up wants to figure out which ones matter.
10x Science raises $4.8M to use AI for identifying promising drug candidates from vast molecular datasets.
Read on TechCrunch →AI research lab NeoCognition secures $40 million in seed funding to develop AI agents capable of human-like learning across various domains.
Why it matters
This funding round for NeoCognition signifies significant investor confidence in the development of more sophisticated AI agents that can learn and adapt like humans. Such advancements have the potential to revolutionize how AI is applied across industries, moving beyond narrow task-specific AI to more general-purpose intelligent systems. The ability for AI to become an expert in any domain could accelerate scientific discovery, improve complex problem-solving, and create new forms of human-AI collaboration.
A new AI company called NeoCognition just got $40 million to build AI that can learn things like people do. This means AI could become an expert in any subject, which is a big step forward.
10x Science raises $4.8M to use AI for identifying promising drug candidates from vast molecular datasets.
Read on TechCrunch →Google Cloud Next 2026 showcased numerous AI startups leveraging its cloud platform.
Read on TechCrunch →SpaceX is reportedly in talks to acquire AI coding startup Cursor, with an option to buy for $60 billion, highlighting the intense competition and strategic moves in the AI developer tools market.
Read on TechCrunch →